Evaluating the Quality of Online Information Regarding Neoadjuvant Therapy for Pancreatic Cancer

Overview

Journal J Gastrointest Cancer

Publisher Springer

Specialties Gastroenterology
Oncology

Date 2022 Nov 3

PMID 36327090

Authors

Lena Stevens

Marissa Guo

Zachary J Brown

Aslam Ejaz

Timothy M Pawlik

Jordan M Cloyd

Affiliations

Soon will be listed here.

Abstract

Purpose: Neoadjuvant therapy (NT) is increasingly utilized for patients with localized pancreatic ductal adenocarcinoma (PDAC). Patients with cancer have high information needs and the Internet has materialized as a leading source of information for many patients. Nevertheless, little is known about the availability, accessibility, quality, and readability of online information regarding NT for PDAC.

Methods: A search of online patient informational materials (PIMs) pertaining to NT for PDAC was conducted using a combination of common search engines and browsers. Two independent researchers evaluated the readability, quality, and availability of unique PIMs from the top 25 websites from each search using validated measures.

Results: Among the 130 websites retrieved, 46 (35.4%) unique PIMs focused on treatment of PDAC. Only 30 (23%) mentioned NT as a possible treatment option. Downstaging was the rationale for NT mentioned in the majority (90%) of websites. The mean quality and reliability of the 30 PIMs, assessed using the DISCERN instrument, was 3.3 ± 0.7, suggesting moderate quality/reliability. The mean readability score, assessed using the SMOG Grade tool, was 10.96 ± 1.49, which is equivalent to an 11th grade reading level.

Conclusion: The low availability, poor readability, and moderate quality of online informational materials regarding NT for PDAC highlight the need for new patient-centered resources to educate patients and caregivers on an increasingly utilized treatment strategy for localized PDAC.

Citing Articles

Reliability of Medical Information Provided by ChatGPT: Assessment Against Clinical Guidelines and Patient Information Quality Instrument.

Walker H, Ghani S, Kuemmerli C, Nebiker C, Muller B, Raptis D J Med Internet Res. 2023; 25:e47479.

PMID: 37389908 PMC: 10365578. DOI: 10.2196/47479.

References

Neoptolemos J, Stocken D, Friess H, Bassi C, Dunn J, Hickey H . A randomized trial of chemoradiotherapy and chemotherapy after resection of pancreatic cancer. N Engl J Med. 2004; 350(12):1200-10. DOI: 10.1056/NEJMoa032295. View

Oettle H, Post S, Neuhaus P, Gellert K, Langrehr J, Ridwelski K . Adjuvant chemotherapy with gemcitabine vs observation in patients undergoing curative-intent resection of pancreatic cancer: a randomized controlled trial. JAMA. 2007; 297(3):267-77. DOI: 10.1001/jama.297.3.267. View

Cloyd J, Shen C, Santry H, Bridges J, Dillhoff M, Ejaz A . Disparities in the Use of Neoadjuvant Therapy for Resectable Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2020; 18(5):556-563. DOI: 10.6004/jnccn.2019.7380. View

Aquina C, Ejaz A, Tsung A, Pawlik T, Cloyd J . National Trends in the Use of Neoadjuvant Therapy Before Cancer Surgery in the US From 2004 to 2016. JAMA Netw Open. 2021; 4(3):e211031. PMC: 7948056. DOI: 10.1001/jamanetworkopen.2021.1031. View

Davis C, Beane J, Gazivoda V, Grandhi M, Greenbaum A, Kennedy T . Neoadjuvant Therapy for Pancreatic Cancer: Increased Use and Improved Optimal Outcomes. J Am Coll Surg. 2022; 234(4):436-443. DOI: 10.1097/XCS.0000000000000095. View

Brown Z, Cloyd J . Trends in the utilization of neoadjuvant therapy for pancreatic ductal adenocarcinoma. J Surg Oncol. 2021; 123(6):1432-1440. DOI: 10.1002/jso.26384. View

Jang J, Han Y, Lee H, Kim S, Kwon W, Lee K . Oncological Benefits of Neoadjuvant Chemoradiation With Gemcitabine Versus Upfront Surgery in Patients With Borderline Resectable Pancreatic Cancer: A Prospective, Randomized, Open-label, Multicenter Phase 2/3 Trial. Ann Surg. 2018; 268(2):215-222. DOI: 10.1097/SLA.0000000000002705. View

Versteijne E, Suker M, Groothuis K, Akkermans-Vogelaar J, Besselink M, Bonsing B . Preoperative Chemoradiotherapy Versus Immediate Surgery for Resectable and Borderline Resectable Pancreatic Cancer: Results of the Dutch Randomized Phase III PREOPANC Trial. J Clin Oncol. 2020; 38(16):1763-1773. PMC: 8265386. DOI: 10.1200/JCO.19.02274. View

Oba A, Ho F, Bao Q, Al-Musawi M, Schulick R, Del Chiaro M . Neoadjuvant Treatment in Pancreatic Cancer. Front Oncol. 2020; 10:245. PMC: 7058791. DOI: 10.3389/fonc.2020.00245. View

10.

Schreiber L, Zeh R, Monsour C, Ejaz A, Tsung A, Pawlik T . Multi-specialty physician perspectives on barriers and facilitators to the use of neoadjuvant therapy for pancreatic ductal adenocarcinoma. HPB (Oxford). 2021; 24(6):833-840. PMC: 9035472. DOI: 10.1016/j.hpb.2021.10.010. View

11.

Stevens L, Brown Z, Zeh R, Monsour C, Wells-Di Gregorio S, Santry H . Characterizing the patient experience during neoadjuvant therapy for pancreatic ductal adenocarcinoma: A qualitative study. World J Gastrointest Oncol. 2022; 14(6):1175-1186. PMC: 9244990. DOI: 10.4251/wjgo.v14.i6.1175. View

12.

Benda N, Veinot T, Sieck C, Ancker J . Broadband Internet Access Is a Social Determinant of Health!. Am J Public Health. 2020; 110(8):1123-1125. PMC: 7349425. DOI: 10.2105/AJPH.2020.305784. View

13.

Huang J, Han Y, Wei J, Liu X, Du Y, Yang L . The effectiveness of the Internet-based self-management program for cancer-related fatigue patients: a systematic review and meta-analysis. Clin Rehabil. 2019; 34(3):287-298. DOI: 10.1177/0269215519889394. View

14.

CHARNOCK D, Shepperd S, Needham G, Gann R . DISCERN: an instrument for judging the quality of written consumer health information on treatment choices. J Epidemiol Community Health. 1999; 53(2):105-11. PMC: 1756830. DOI: 10.1136/jech.53.2.105. View

15.

De Groot L, Harris I, Regehr G, Tekian A, Ingledew P . Quality of Online Resources for Pancreatic Cancer Patients. J Cancer Educ. 2017; 34(2):223-228. DOI: 10.1007/s13187-017-1290-8. View

16.

Storino A, Castillo-Angeles M, Watkins A, Vargas C, Mancias J, Bullock A . Assessing the Accuracy and Readability of Online Health Information for Patients With Pancreatic Cancer. JAMA Surg. 2016; 151(9):831-7. DOI: 10.1001/jamasurg.2016.0730. View

17.

Hutchinson N, Baird G, Garg M . Examining the Reading Level of Internet Medical Information for Common Internal Medicine Diagnoses. Am J Med. 2016; 129(6):637-9. DOI: 10.1016/j.amjmed.2016.01.008. View

18.

Tangri V, Chande N . Quality of Internet-based information on gastrointestinal diseases. Can J Gastroenterol. 2011; 25(2):93-6. PMC: 3043011. DOI: 10.1155/2011/345076. View

19.

Charow R, Snow M, Fathima S, Giuliani M, McEwan K, Winegust J . Evaluation of the scope, quality, and health literacy demand of Internet-based anal cancer information. J Med Libr Assoc. 2019; 107(4):527-537. PMC: 6774557. DOI: 10.5195/jmla.2019.393. View

20.

Sajid M, Iftikhar M, Monteiro R, Miles A, Woods W, Baig M . Internet information on colorectal cancer: commercialization and lack of quality control. Colorectal Dis. 2007; 10(4):352-6. DOI: 10.1111/j.1463-1318.2007.01316.x. View